Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development (1) | 60,411 | 41,623 |
| General and administrative (2) | 15,230 | 11,944 |
| Gain on sale of in-process research and development asset | (30,000) | — |
| Total operating expenses | 45,641 | 53,567 |
| Loss from operations | (45,641) | (53,567) |
| Other (expense) income: | ||
| Interest income | 6,995 | 6,493 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s G&A?
- Spyre Therapeutics, Inc. (SYRE) reported G&A of $15.23M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s G&A changed year-over-year?
- Spyre Therapeutics, Inc.'s G&A increased by 27.5% year-over-year, from $11.94M to $15.23M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s G&A?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s G&A has grown at a 15.1% compound annual growth rate (CAGR), from $27.32M to $47.91M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Spyre Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude